- Previous Close
0.099 - Open
0.100 - Bid 0.097 x --
- Ask 0.100 x --
- Day's Range
0.096 - 0.101 - 52 Week Range
0.041 - 0.247 - Volume
512,600 - Avg. Volume
12,020,152 - Market Cap (intraday)
80.106M - Beta (5Y Monthly) -0.40
- PE Ratio (TTM)
5.00 - EPS (TTM)
0.020 - Earnings Date Feb 25, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 17, 2015
- 1y Target Est
--
Universal Health International Group Holding Limited, an investment holding company, distributes and retails drugs, healthcare products, and other pharmaceutical products in the northeastern region of the People's Republic of China. Its product categories include Chinese patent medicines, chemical preparations, antibiotics and biochemical drugs, traditional Chinese medicine decoction pieces, biological products, protein assimilation preparations, peptide hormones, disinfection products, blood products, medical equipment, prepackaged food, health care products, nutritional food, stereotyped packaging cosmetics, and daily necessities, as well as family planning supplies, such as contraceptives and utensils; and dairy products, including infant formula milk powder. The company also provides storage services. The company was formerly known as Jintian Pharmaceutical Group Limited and changed its name to Universal Health International Group Holding Limited in July 2015. Universal Health International Group Holding Limited was founded in 1998 and is headquartered in Shenyang, the People's Republic of China.
www.uhighl.com1,198
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: 2211.HK
View MorePerformance Overview: 2211.HK
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2211.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2211.HK
View MoreValuation Measures
Market Cap
80.11M
Enterprise Value
49.79M
Trailing P/E
4.30
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.07
Price/Book (mrq)
0.22
Enterprise Value/Revenue
0.05
Enterprise Value/EBITDA
3.12
Financial Highlights
Profitability and Income Statement
Profit Margin
1.42%
Return on Assets (ttm)
-1.00%
Return on Equity (ttm)
4.16%
Revenue (ttm)
938.85M
Net Income Avi to Common (ttm)
13.33M
Diluted EPS (ttm)
0.020
Balance Sheet and Cash Flow
Total Cash (mrq)
50.71M
Total Debt/Equity (mrq)
6.46%
Levered Free Cash Flow (ttm)
-85.1M